Transient hair loss during treatment with dimethyl-fumarate for multiple sclerosis.

Abstract

INTRODUCTION:

Dimethyl-fumarate is a recently approved drug for relapsing-remitting Multiple Sclerosis in Italy.

CLINICAL CASE:

A 55-year-old woman started therapy with dimethyl-fumarate on June 2014; it was well-tolerated aside from moderate flushing. Starting September 2014 she noticed a progressive hair loss, that neither the dermatological examination nor clinical and medical history nor blood investigations could explain. The hair loss slowed down after two months and was followed by a hair growth back.

DISCUSSION:

Transient hair loss is not a reported side effect of dimethyl-fumarate therapy but by excluding any known cause we attributed it to the beginning of the new therapy.

• Authors: Francesco Antonio Losavio, Matteo Lucchini, Chiara De Fino, Massimiliano Mirabella, Viviana Nociti
• Journal: Multiple sclerosis and related disorders (Mult Scler Relat Disord) Vol. 7 Pg. 68-9 (May 2016) ISSN: 2211-0356 [Electronic] Netherlands
• PMID: 27237761 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2016 Elsevier B.V. All rights reserved.

Chemical References

• Immunosuppressive Agents
• Dimethyl Fumarate

Topics

• Alopecia (chemically induced, pathology)
• Dimethyl Fumarate (adverse effects, therapeutic use)
• Female
• Humans
• Immunosuppressive Agents (adverse effects, therapeutic use)
• Middle Aged
• Multiple Sclerosis, Relapsing-Remitting (drug therapy, pathology)